Rate My Professor Byron Creese

Dr Byron Creese is Senior Lecturer and Director of Research in the Department of Psychology at Brunel University London, within the College of Health, Medicine and Life Sciences. He is a translational researcher whose work focuses on neuropsychiatric symptoms in dementia and late-life onset neuropsychiatric symptoms as markers of neurodegenerative disease. His research employs approaches from psychology to genomics and epidemiology to investigate disease mechanisms and clinical consequences, drawing on experience with large longitudinal datasets, proxy-reported and self-reported outcomes, and complex statistical modelling. Dr Creese received his PhD from King’s College London and completed postdoctoral research positions at King’s College London and the University of Exeter before joining Brunel University London in 2023. In addition to his academic role, he provides research-led consultancy to MedTech and pharmaceutical organisations through the university, with expertise in real-world evidence, behavioural and cognitive outcomes, and neuropsychiatric symptoms, particularly in the contexts of ageing, dementia, and mental health. He supports partners with study design, advanced analysis of real-world and patient-reported outcomes data, interpretation of behavioural, neuropsychiatric, and cognitive endpoints, and evidence generation for value propositions, payer conversations, and regulatory engagement. Dr Creese is actively involved in mentoring students and fostering the next generation of dementia researchers. His recent publications include work on epigenomic subtypes of late-onset Alzheimer’s disease, the acceptability of wearable prototypes to detect agitation in dementia, risks associated with risperidone in dementia, recommendations for management of psychosis in neurodegenerative disease, and multiomic approaches to heterogeneity in Alzheimer’s disease.

Dr Creese maintains an active research profile with numerous peer-reviewed publications addressing topics such as genetic risk for Alzheimer’s disease, psychotic symptoms in Alzheimer’s disease, and mild behavioural impairment. He contributes to the field through involvement in international working groups and collaborative projects on neuropsychiatric symptoms and dementia.